immunotherapy

Health By Sharon Begley

Roche scores first U.S. approval of immunotherapy for breast cancer

First Opinion By Neil Canavan

Cartoons offer a peek into cancer immunotherapy — and scientists’ minds

First Opinion By Doreen Carvajal

Male doctors said my ‘female’ cancer was incurable. Then a woman took command and gave me hope

First Opinion By Ankur Parikh

We need more answers about immunotherapy for the elderly

Adam's Take By Adam Feuerstein

A biotech seeking IPO riches limited disclosure of patient deaths tied to immunotherapy

Health By Associated Press

In a milestone year, gene therapy is finding a place in medicine

Lab Chat By Megan Thielking

Insight into exhausted immune cells could open new doors for cancer therapy

Biotech By Damian Garde

Separating hope from hype in the latest cancer treatment ‘revolution’

Biotech By Damian Garde

Novel cancer treatment from Kite Pharma notches positive results, but big questions remain

Biotech By Meghana Keshavan

Hurdles abound in race to bring customized cancer treatments to masses

In the Lab By Sharon Begley

In cancer, it’s back to the future as old treatments make cutting-edge ones more effective

Health By Rebecca Robbins

For cancer patients on experimental immunotherapy drugs, it’s been an emotional week

Biotech By Damian Garde

FDA lets cancer trial resume after three patient deaths

Biotech By Sharon Begley

In Juno patient deaths, echoes seen of earlier failed company

Biotech By Damian Garde

After a deadly clinical trial, will immune therapies for cancer be a bust?

Biotech By Damian Garde and Meghana Keshavan

Juno halts its immunotherapy trial for cancer after three patient deaths

Business By Sharon Begley

Sean Parker’s put up big bucks for cancer. We’ve got questions

Politics By Dylan Scott

As Johns Hopkins launches new cancer center, Biden sees a model for his ‘moonshot’

Quick Take By Megan Thielking

These antibodies could protect against Ebola’s harms, but results come with a caveat